Synmosa Biopharma (4114) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 健喬

Synmosa Biopharma (4114) reported revenue of NT$766.6 million for Oct 2026, +41.2% year on year and +2.6% from the previous month. Revenue for Jan–Oct 2026 was NT$6.61 billion (+28.5% year on year).

Year-on-year revenue growth: 8 months in a row. →

In Oct 2026, it ranked No. 7 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$497.2 million24/10Nov 2024 NT$498.1 millionDec 2024 NT$521.1 millionJan 2025 NT$506.2 millionFeb 2025 NT$466.7 million25/02Mar 2025 NT$479.7 millionApr 2025 NT$502.5 millionMay 2025 NT$532.1 millionJun 2025 NT$574.6 million25/06Jul 2025 NT$495.5 millionAug 2025 NT$503.2 millionSep 2025 NT$538.6 millionOct 2025 NT$543 million25/10Nov 2025 NT$502.6 millionDec 2025 NT$543.7 millionJan 2026 NT$634.9 millionFeb 2026 NT$430.3 million26/02Mar 2026 NT$562.6 millionApr 2026 NT$570.4 millionMay 2026 NT$600.8 millionJun 2026 NT$750.9 million26/06Jul 2026 NT$791.7 millionAug 2026 NT$754.3 millionSep 2026 NT$747 millionOct 2026 NT$766.6 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$766.6 million+41.2%+2.6%
Sep 2026NT$747 million+38.7%-1.0%
Aug 2026NT$754.3 million+49.9%-4.7%
Jul 2026NT$791.7 million+59.8%+5.4%
Jun 2026NT$750.9 million+30.7%+25.0%
May 2026NT$600.8 million+12.9%+5.3%
Apr 2026NT$570.4 million+13.5%+1.4%
Mar 2026NT$562.6 million+17.3%+30.8%
Feb 2026NT$430.3 million-7.8%-32.2%
Jan 2026NT$634.9 million+25.4%+16.8%
Dec 2025NT$543.7 million+4.3%+8.2%
Nov 2025NT$502.6 million+0.9%-7.4%
Oct 2025NT$543 million+9.2%+0.8%
Sep 2025NT$538.6 million+21.7%+7.0%
Aug 2025NT$503.2 million+2.0%+1.6%
Jul 2025NT$495.5 million+1.3%-13.8%
Jun 2025NT$574.6 million+51.5%+8.0%
May 2025NT$532.1 million+10.2%+5.9%
Apr 2025NT$502.5 million+6.6%+4.7%
Mar 2025NT$479.7 million+14.9%+2.8%
Feb 2025NT$466.7 million+62.3%-7.8%
Jan 2025NT$506.2 million-12.9%-2.9%
Dec 2024NT$521.1 million+20.1%+4.6%
Nov 2024NT$498.1 million+12.2%+0.2%
Oct 2024NT$497.2 million+10.1%+12.4%

Jan–Oct 2026 cumulative: NT$6.61 billion (+28.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Synmosa Biopharma vs PEC / Synmosa Biopharma vs Lotus Pharm / Synmosa Biopharma vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Y.S.H.3705NT$749.4 million+4.4%
GKB1707NT$748.3 million-30.8%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16